Significant link between sCD30 changes and HIV viremia in patients treated with HAART

Priscilla Biswas, Alessandro Cozzi-Lepri, Fanny Delfanti, Andrea Galli, Vincenzo Colangeli, Maria Cristina Moioli, Antonella Scarchilli, Nicola Abrescia, Gianmarco Vigevani, Antonella D'Arminio-Monforte, Roberto Novati, Adriano Lazzarin

Research output: Contribution to journalArticle

Abstract

Elevated sCD30 levels were generally associated with poor prognosis in chronic HIV infection prior to the era of highly active antiretroviral therapy (HAART). Little information is available on sCD30 and HIV-1 viremia. In this study, the association between sCD30 and HIV-1 viremia was investigated in HIV-infected patients who underwent HAART. sCD30 was measured in 276 patients prior (T0) and 6 months after HAART (T6). Standard survival analyses were used to evaluate the prognostic value of sCD30 and sCD30 change from baseline to predict the virological response to HAART. Higher levels (>30 U/ml) of sCD30 prior to HAART were associated with relatively higher viremia (P = 0.0001) and tended to be associated with a lower chance of achieving virological success (P = 0.13). The median T6 sCD30 level in patients who concomitantly had viremia >500 copies/ml was higher than the median sCD30 level of those with viremia ≤500 copies/ml (P = 0.002). Conversely, within the patients who achieved viral suppression on HAART, those who had concomitantly a larger reduction in sCD30 subsequently experienced a higher rate of virological failure (P = 0.04). A strong, but complex, link exists between sCD30 levels and HIV viremia in the era of HAART. The change in sCD30 levels from pre-therapy to the date of first viral suppression could be used to identify patients who are more likely to experience later virological rebound among those who achieve initially virological success.

Original languageEnglish
Pages (from-to)1513-1519
Number of pages7
JournalJournal of Medical Virology
Volume78
Issue number12
DOIs
Publication statusPublished - Dec 2006

    Fingerprint

Keywords

  • Antiretroviral therapy
  • Immune activation
  • TNF receptor family
  • Viral load
  • Viral rebound
  • Viral success

ASJC Scopus subject areas

  • Virology

Cite this

Biswas, P., Cozzi-Lepri, A., Delfanti, F., Galli, A., Colangeli, V., Moioli, M. C., Scarchilli, A., Abrescia, N., Vigevani, G., D'Arminio-Monforte, A., Novati, R., & Lazzarin, A. (2006). Significant link between sCD30 changes and HIV viremia in patients treated with HAART. Journal of Medical Virology, 78(12), 1513-1519. https://doi.org/10.1002/jmv.20733